Portfolio Lab

Ascendis Pharma A/S

  • Stock
  • Ticker ASND
  • ISIN DK0060615755
  • Nasdaq
  • US listing in dollars

Health care · Pharmaceuticals · Denmark

$252.73 −1.26%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Ascendis Pharma A/S since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ASNDGlobal equities (VT)

$10,000 grew to $123,887. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −61.7% in 04/2023, measured from the peak in 12/2020. It took 56 months to get back to the old peak.

1-year return
+20.6%
5-year return p.a.
+11.2%
10-year return p.a.
+28.6%
Volatility p.a.
43.1%
Largest decline
−61.7%

Financial statements

Amounts in € millions from the company's annual financial reports, earnings per share in € per ordinary share

Fiscal year2022202320242025
Income statement
Revenue51267364720
Gross profit39222319625
Operating income-562-456-279-136
Net income-583-481-378-228
Earnings per share-0.10-0.090.07-0.04
Balance sheet
Total assets1,0908261,1791,303
Liabilities8269711,2851,465
Equity263-146-106-163
Cash445392560616
Long-term debt388534365385
Cash flow
Operating cash flow-496-467-30654
Capital expenditure-14-2.4––
Free cash flow-510-470––

Annual returns

Best year 2019 at +122.1%, weakest 2021 at −19.3%. 7 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
–
Market cap in trading currency
–
Enterprise value
–
P/E
–
P/S
–
P/B
–
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
–

Results (latest fiscal year)

Revenue
$791m
Gross profit
$687m
EBITDA
–
Net income
−$251m
Earnings per share
–
Revenue growth
+98.0%
Earnings growth
–

Profitability

Gross margin
86.8%
Operating margin
-18.9%
Net margin
-31.7%
Return on equity
–
Return on assets
-17.5%

Balance sheet and cash flow

Cash
$677m
Financial debt
$486m
Debt/equity %
–
Current ratio
1.04
Book value per share
–
Operating cash flow
$59.2m
Free cash flow
–

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
–
Volume
554,235
Avg. volume 3 months
756,641
Relative volume
0.7

Price and technicals

Price
$252.73
1 day
−1.3%
52-week high
$277.18
52-week low
$196.63
Distance to 52-week high
−8.8%
Distance to 52-week low
+28.5%
Distance to 50-day line
+4.2%
Distance to 200-day line
+5.0%
RSI (14)
49
Volatility 1M
30.8%

Performance

1 week
−8.2%
1 month
+4.0%
3 months
+0.3%
6 months
+6.2%
YTD
+18.5%
1 year
+23.6%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has ASND performed since 11/2016?

$10,000 grew to $123,887 by 20 Nov 2026, which is +28.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ASND?

Volatility was 43.1% per year, measured on monthly returns. The largest decline from a peak was −61.7%, with the low in 04/2023.

How does ASND compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ASND returned +28.6% at 43.1%. The correlation of monthly returns was 0.21; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Ascendis Pharma A/S (ASND): Return and risk | Portfolio Lab